1,000+ R&D leaders advancing CNS drug development

November 1 to 4, 2026 at Encore Boston Harbor, Boston. Clinical development, feasibility and innovation leaders working on neurology and psychiatry programs.
1,000+ R&D leaders advancing CNS drug development

CNS trials are among the hardest to enroll.
The eligible patients are scattered, the criteria are tight, and the sites that look strong on paper often cannot deliver the ramp. Inferring feasibility from registries and past trial counts is exactly where CNS programs go wrong.
We count the protocol-qualifying patients each investigator can actually reach and pair that with their real enrollment record. On a CNS protocol, that is the difference between a site list that looks good and one that holds up when the ramp starts.
A live walk-through of a recent, de-identified rare-disease study: what each eligibility criterion cost in qualifying patients, and how the final protocol qualified nearly three times the patients of the draft.
The deliverable itself: sites paired with counted qualifying patients and an investigator who has enrolled that population before, including strong sites no reputation list would surface.
You send us the CNS protocol. In days you get the same read on your own study: the count, the sites that can reach those patients, and the reasoning. Nothing for your team to install or run.
Spent years on the operating side of trials before starting Quantum Research Cloud. Tell him the indication you are working in and he will walk you through the deliverable on a real program, then what the same read would look like on your study.
Encore Boston Harbor
1 Broadway, Everett, MA 02149
Organized by CNS Summit.
CNS Summit is the annual gathering of more than a thousand R&D leaders working on neurology and psychiatry drug development: sponsors, CROs, technology partners and investigators. Four days of sessions cover CNS clinical trial design, patient recruitment, digital measures and the operational realities of enrolling trials in Alzheimer’s disease, Parkinson’s disease, depression, schizophrenia, epilepsy and rare neurological conditions. Quantum Research Cloud attends because CNS feasibility is where inferred site data fails most often, and where counted, patient-level evidence changes the site list.
Will Quantum Research Cloud be at CNS Summit 2026?
Yes. Dustin Caldwell, our Chief Executive Officer, will be at CNS Summit from November 1 to 4, 2026 at Encore Boston Harbor in Boston, meeting with CNS sponsors and CROs about clinical trial feasibility and site selection for neurology and psychiatry programs.
How do I book a meeting with Quantum Research Cloud at CNS Summit?
Email Dustin at dustin@quantumresearch.cloud with your indication and the times that suit you, or use the contact form on this site. He confirms a slot before the event.
Why does Quantum Research Cloud focus on CNS trials?
CNS trials are among the hardest to enroll: eligible patients are scattered, criteria are tight, and sites that look strong on paper often cannot deliver the ramp. Counting protocol-qualifying patients from real patient data, and pairing that with each investigator’s real enrollment record, is where we change the outcome.
Where is CNS Summit 2026 held?
At Encore Boston Harbor, 1 Broadway, Everett, Massachusetts, across the river from downtown Boston, from November 1 to 4, 2026.
Tell us the indication and what you are working on. We will confirm a slot at CNS Summit and come prepared.
Emails go straight to Dustin at dustin@quantumresearch.cloud. He confirms a slot before the event.